MedTrace Logo

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

NCT02338843 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2018-03-27

Study results available
· View outcomes & findings →

Summary

This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.

Conditions

  • Catecholamine-resistant Hypotension (CRH)
  • Distributive Shock
  • High Output Shock
  • Sepsis

Interventions

DRUG

LJPC-501

Treatment arm

DRUG

Placebo

PBO

Sponsors & Collaborators

  • La Jolla Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • George F Tidmarsh, MD, PhD · La Jolla Pharmaceutical Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-12-01
Completion
2017-02-18

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Finland
  • France
  • Germany
  • New Zealand
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338843 on ClinicalTrials.gov